Recent progresses of exosome–liposome fusions in drug delivery

IF 9.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Chinese Chemical Letters Pub Date : 2023-06-04 DOI:10.1016/j.cclet.2023.108647

Lulu Zheng , Bo Hu , Deyao Zhao , Wenjing Liu , Qing Liu , Yuanyu Huang , Shaobo Ruan

{"title":"Recent progresses of exosome–liposome fusions in drug delivery","authors":"Lulu Zheng , Bo Hu , Deyao Zhao , Wenjing Liu , Qing Liu , Yuanyu Huang , Shaobo Ruan","doi":"10.1016/j.cclet.2023.108647","DOIUrl":null,"url":null,"abstract":"<div><p>Exosomes are membrane-bound nanoscale extracellular vesicles, which produced by almost all organisms. Due to the excellent biocompatibility, long circulation time as well as low immunogenicity, exosomes as naturally-derived drug delivery carriers have experienced explosive growth over the past decades. However, issues such as insufficient loading efficiency, heterogeneous delivery efficiency, uncontrollable targeting ability, and low production limit their wide application. Recently, the emerging exosome–liposome fusion strategy has become a potential approach to solve such issues. Thus, this review mainly focuses on the currently developed exosome–liposome fusion strategy and their application in drug delivery as well as disease treatment. This review aims to shed light on the advantages of fusion strategy in drug delivery and provides a better understanding for more rational design. The current challenge and future perspective regarding their clinical translation and application will also be discussed.</p></div>","PeriodicalId":10088,"journal":{"name":"Chinese Chemical Letters","volume":"35 2","pages":"Article 108647"},"PeriodicalIF":9.4000,"publicationDate":"2023-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Chemical Letters","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S100184172300493X","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 1

Abstract

Exosomes are membrane-bound nanoscale extracellular vesicles, which produced by almost all organisms. Due to the excellent biocompatibility, long circulation time as well as low immunogenicity, exosomes as naturally-derived drug delivery carriers have experienced explosive growth over the past decades. However, issues such as insufficient loading efficiency, heterogeneous delivery efficiency, uncontrollable targeting ability, and low production limit their wide application. Recently, the emerging exosome–liposome fusion strategy has become a potential approach to solve such issues. Thus, this review mainly focuses on the currently developed exosome–liposome fusion strategy and their application in drug delivery as well as disease treatment. This review aims to shed light on the advantages of fusion strategy in drug delivery and provides a better understanding for more rational design. The current challenge and future perspective regarding their clinical translation and application will also be discussed.

Abstract Image

查看原文本刊更多论文

外泌体-脂质体融合在药物递送中的最新进展

外泌体是膜结合的纳米级细胞外囊泡，几乎所有生物都能产生。外泌体由于其良好的生物相容性、较长的循环时间和较低的免疫原性，在过去的几十年里，作为天然衍生的药物传递载体得到了爆炸性的发展。但其装载效率不高、输送效率不均匀、靶向能力不可控、产量低等问题限制了其广泛应用。最近，新兴的外泌体-脂质体融合策略已成为解决此类问题的潜在途径。因此，本文主要对近年来发展的外泌体-脂质体融合策略及其在药物传递和疾病治疗中的应用进行综述。本文旨在揭示融合策略在给药过程中的优势，为更合理的给药设计提供依据。本文还将讨论目前面临的挑战和未来对其临床翻译和应用的展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chinese Chemical Letters 化学-化学综合

CiteScore

14.10

自引率

15.40%

发文量

8969

审稿时长

1.6 months

期刊介绍： Chinese Chemical Letters (CCL) (ISSN 1001-8417) was founded in July 1990. The journal publishes preliminary accounts in the whole field of chemistry, including inorganic chemistry, organic chemistry, analytical chemistry, physical chemistry, polymer chemistry, applied chemistry, etc.Chinese Chemical Letters does not accept articles previously published or scheduled to be published. To verify originality, your article may be checked by the originality detection service CrossCheck.